Infant Bacterial Therapeutics AB (IBT B):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Infant Bacterial Therapeutics AB (IBT B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8135)・商品コード:DATA904C8135
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:34
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥55,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥83,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops drugs influencing the human infant microbiome to treat rare diseases in premature infants. Its pipeline product candidates include IBP-9414, containing the active substance Lactobacillus reuteri, co-evolved human bacterial strain derived from human breast milk, used for the prevention of Necrotizing enterocolitis (NEC); and IBP-1016, a drug candidate used for the treatment of gastroschisis, a severe disease in infants. The company develops pharmaceutical drug candidates for gastrointestinal neonatal condition that causes mucosal injury, necrosis, perforation in the intestinal tracts of infants and death. It operates through a network of neonatologists and research groups. IBT is headquartered in Stockholm City, Sweden.

Infant Bacterial Therapeutics AB (IBT B) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 10
Equity Offering 11
Infant Bacterial Therapeutics Raises USD52.4 Million in Rights Offering of Shares 11
Infant Bacterial Therapeutics Raises USD18 Million in Private Placement of Shares 13
Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 15
BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 16
BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 17
Infant Bacterial Therapeutics AB – Key Competitors 18
Infant Bacterial Therapeutics AB – Key Employees 19
Infant Bacterial Therapeutics AB – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Aug 28, 2017: Infant Bacterial Therapeutics: Interim Management Statement, January 1 – June 30, 2017 21
May 04, 2017: Infant Bacterial Therapeutics: Interim Management Statement, January 1 – March 31, 2017 24
Feb 14, 2017: Infant Bacterial Therapeutics Interim report January 1 – December 31 2016 25
Corporate Communications 26
May 09, 2018: Infant Bacterial Therapeutics Nomination Committee modifies its proposal to the Board of Directors 26
Mar 10, 2017: InfantBacterial Therapeutics has been approved for listing on Nasdaq First North’s Premier segment 27
Product News 28
Jun 26, 2018: IBT plans to start its phase 3 study in the second half of 2018 and contracts CRO 28
Clinical Trials 29
Sep 11, 2017: Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups 29
Jan 24, 2017: Last patient enrolled in IBT’s Phase 2 study 30
Other Significant Developments 31
Aug 16, 2018: Infant Bacterial Therapeutics interim management statement, January 1 – June 30, 2018 31
Feb 28, 2018: Infant Bacterial Therapeutics Interim Management Statement, January 1 – December 31, 2017 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Infant Bacterial Therapeutics AB, Deals By Therapy Area, 2012 to YTD 2018 8
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 10
Infant Bacterial Therapeutics Raises USD52.4 Million in Rights Offering of Shares 11
Infant Bacterial Therapeutics Raises USD18 Million in Private Placement of Shares 13
Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 15
BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 16
BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 17
Infant Bacterial Therapeutics AB, Key Competitors 18
Infant Bacterial Therapeutics AB, Key Employees 19
Infant Bacterial Therapeutics AB, Subsidiaries 20

List of Figures
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Infant Bacterial Therapeutics AB (IBT B):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8135)販売に関する免責事項を必ずご確認ください。
★調査レポート[Infant Bacterial Therapeutics AB (IBT B):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆